(64/368 (17.3%) v 76/338 (22.6%); adjusted relative risk 0.78; 95% CI 0.58 to 1.06; P=0.11).
47
Eczema was the most common allergic disease; 13.8% of children in the n-3 LCPUFA group antibodies potentially leading to sensitisation to allergens. However when diets are high in n-77 3 long-chain (LC) PUFA (from fatty fish and fish oils) they are readily incorporated into 78 cellular phospholipids and thereby displace AA and alter membrane composition and fluidity.
79
This leads to a range of immunological effects, including reduction of prostaglandin E 2 80 synthesis (1, 2) providing a plausible mechanism by which diets high in n-3 LCPUFA may 81 modulate the development of IgE-mediated allergic disease.
83
In support of this biological mechanism, epidemiological studies have reported that increased 84 maternal fish intake during pregnancy is associated with reduced atopic or allergic outcomes 85 in children (3-7). Furthermore, evidence from randomised controlled trials (RCTs) (8-11) Our study was specifically designed to assess the effect of n-3 LCPUFA supplementation, 92 predominantly as DHA, in pregnancy on the cumulative incidence of IgE-mediated allergic The dietary treatments for the DOMInO trial have been previously described (13). Briefly,
113
women allocated to the n-3 LCPUFA group were asked to consume three 500 mg capsules of 114 fish oil concentrate, providing 800 mg of DHA and 100 mg of eicosapentaenoic acid (EPA); 115 women in the control group were asked to take three 500 mg vegetable oil capsules without 116 n-3 LCPUFA daily. This was a double-blinded study; all capsules were similar in size, shape 117 and colour. Women took capsules from 21 weeks' gestation until delivery. Eczema was defined as the presence of eczema (criteria according to (14)) on medical review 142 or a history of an itchy rash distributed to the facial, flexural, or extensor surface of the skin 143 that had followed a fluctuating or chronic course. We defined IgE-associated eczema or 144 atopic eczema as eczema with sensitisation to at least one of the allergens assessed. IgE- 
Statistical methods

157
With >328 children per treatment group we would be able to detect an absolute reduction of were compared between groups using Fisher's exact tests on the original (unimputed) data.
168
Negative binomial regression models were used to analyse count outcomes, with the effect of 169 treatment expressed as a ratio of means. Both unadjusted and adjusted analyses were 
Results
180
The allergy follow-up trial profile is shown in Figure 1 (Tables 2 and 3) . Table 3 reports the allergic disease outcomes at 3 years of age and demonstrates that there 215 were no differences between the n-3 LCPUFA and control groups. The percentage of 216 children diagnosed with eczema with sensitisation at 3 years of age was 13.0% and higher
217
than that reported at 1 year of age (9.2% (11) have IgE-associated eczema at 1 year of age.
221
There was no difference between the groups in sensitisation to at least one allergen at 1 or 3 222 years of age, with 29.4% of children in the n-3 LCPUFA group sensitised compared with 223 35.2% in the control group (adjusted relative risk 0.85; 95% CI 0.68 to 1.06; P=0.14; Table   224 2). At 3 years of age, 24.6% of children in the n-3 LCPUFA group compared with 26.1% in 225 the control group were sensitised to at least one allergen (adjusted relative risk 0.96; 95% CI cheap.
250
The lower incidence of IgE-associated eczema observed at 1 year of age in the n-3 LCPUFA 251 group did not persist at 3 years of age. As more than half of the children diagnosed with 2700mg/day (10,12) to 3700mg/day (8) and it may be that higher n-3 LCPUFA doses are 264 needed to result in reduced allergic disease outcomes. Dose, timing and duration of n-3
265
LCPUFA supplementation are important considerations and worthy of further investigation.
266
A limitation of our study was that we have not taken blood samples from the children and 267 hence cannot report on their n-3 LCPUFA plasma phospholipids levels at 1 or 3 years of age.
269
The pattern of allergic disease is known to differ with age, with the greatest incidence of food 
